US · UG · HOUSEHOLD & PERSONAL PRODUCTS
United-Guardian, Inc. (UG) intrinsic value and stock valuation
$7.35as of 2026-11-21 · Mkt cap 33.13M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
United-Guardian, Inc. DCF and intrinsic value
InvestorsCraft values UG with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from UG’s statements →
United-Guardian, Inc. Graham Number
Graham Number: $5.03d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- BranchOut Food Inc. (BOF) $1.77
- Jianzhi Education Technology Group Company Limited (JZ) $1.43
- Coffee Holding Co., Inc. (JVA) $4.93
- Big Tree Cloud Holdings Limited (DSY) $2.65
- iHuman Inc. (IH) $0.84
- Australian Oilseeds Holdings Limited Ordinary Shares (COOT) $0.30
- Mannatech, Incorporated (MTEX) $2.56
- Bonk, Inc. (BNKK) $0.46
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $10.6M | $12.2M | $10.9M | $12.7M | $13.9M |
| Operating income | $2.24M | $3.65M | $2.86M | $4.04M | $5.67M |
| Net income | $2.11M | $3.25M | $2.58M | $2.57M | $4.66M |
| EPSd | $459.7K | $708.1K | $562.1K | $559.9K | $1.02M |
| Operating cash flow | $1.97M | $3.47M | $3.14M | $2.53M | $5.31M |
| Capital expenditure | -$-60K | -$-430K | -$-170K | -$-80K | -$-120K |
| Free cash flow | $1.91M | $3.03M | $2.98M | $2.45M | $5.2M |
| Total assets | $13.1M | $13.8M | $12.9M | $10.6M | $12.2M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net debt | -$-1.25M | -$-1.88M | -$-8.24M | -$-830K | -$-530K |
| Total equity | $11.2M | $11.9M | $11.4M | $9.27M | $9.82M |
| Cash and short-term investments | $8.57M | $9.4M | $9.09M | $6.48M | $8.17M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $10.6M | $12.2M | $10.9M | $12.7M | $13.9M |
| Cost of revenue | $5.51M | $5.72M | $5.48M | $6M | $5.75M |
| Gross profit | $5.03M | $6.46M | $5.41M | $6.7M | $8.18M |
| Research and development expenses | $460K | $460K | $460K | $490K | $480K |
| Selling, general and administrative expenses | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Other expenses | $2.33M | $2.36M | $2.08M | $2.17M | $2.04M |
| Operating expenses | $2.79M | $2.81M | $2.54M | $2.66M | $2.51M |
| Cost and expenses | $8.3M | $8.54M | $8.02M | $8.66M | $8.26M |
| Interest income | $370K | $430K | $310K | $240K | $230K |
| Interest expense | $0.00 | $0.00 | $0.00 | $1.62M | $0.00 |
| Depreciation and amortization | $110K | $100K | $110K | $140K | $150K |
| Ebitda | $2.75M | $4.2M | $3.36M | $4.98M | $6.02M |
| Operating income | $2.24M | $3.65M | $2.86M | $4.04M | $5.67M |
| Total other income/expenses, net | $400K | $460K | $390K | -$-810K | $210K |
| Income before tax | $2.64M | $4.11M | $3.25M | $3.23M | $5.88M |
| Income tax expense | $540K | $860K | $670K | $660K | $1.22M |
| Net income | $2.11M | $3.25M | $2.58M | $2.57M | $4.66M |
| Weighted average shares outstanding | $4.59M | $4.59M | $4.59M | $4.59M | $4.59M |
| Weighted average diluted shares outstanding | $4.59M | $4.59M | $4.59M | $4.59M | $4.59M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $8.57M | $9.4M | $9.09M | $6.48M | $8.17M |
| Net receivables | $1.59M | $1.43M | $1.57M | $1.43M | $1.81M |
| Inventory | $1.51M | $1.45M | $1.22M | $1.67M | $1.41M |
| Total current assets | $12.2M | $12.7M | $12.3M | $9.97M | $11.6M |
| Property, plant and equipment, net | $910K | $960K | $620K | $560K | $660K |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $910K | $1.13M | $670K | $670K | $660K |
| Total assets | $13.1M | $13.8M | $12.9M | $10.6M | $12.2M |
| Accounts payable | $480K | $430K | $130K | $30K | $410K |
| Short-term debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Deferred revenue | $10K | $0.00 | $20K | $0.00 | $190K |
| Total current liabilities | $1.67M | $1.91M | $1.53M | $1.37M | $2.34M |
| Long-term debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $210K | $0.00 | $0.00 | $0.00 | $80K |
| Capital lease obligations | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total liabilities | $1.88M | $1.91M | $1.53M | $1.37M | $2.42M |
| Common stock | $460K | $460K | $460K | $460K | $460K |
| Retained earnings | $10.8M | $11.4M | $10.9M | $8.81M | $9.36M |
| Accumulated other comprehensive income (loss) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total equity | $11.2M | $11.9M | $11.4M | $9.27M | $9.82M |
| Total investments | $7.32M | $7.52M | $850K | $5.65M | $7.64M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net debt | -$-1.25M | -$-1.88M | -$-8.24M | -$-830K | -$-530K |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $2.11M | $3.25M | $2.58M | $2.57M | $4.66M |
| Depreciation and amortization | $110K | $100K | $110K | $140K | $150K |
| Stock-based compensation | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Change in working capital | -$-600K | $290K | $510K | -$-1.06M | $560K |
| Accounts receivable | -$-160K | $140K | -$-140K | $390K | -$-430K |
| Inventory | -$-50K | -$-210K | $470K | -$-290K | $0.00 |
| Accounts payable | $60K | $290K | $100K | -$-380K | $380K |
| Net cash provided by operating activities | $1.97M | $3.47M | $3.14M | $2.53M | $5.31M |
| Investments in property, plant and equipment | -$-60K | -$-430K | -$-170K | -$-80K | -$-120K |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $40K | $120K |
| Net cash used for investing activities | $180K | -$-7.08M | $4.73M | $900K | -$-180K |
| Common stock issued | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | -$-2.77M | -$-2.76M | -$-460K | -$-3.12M | -$-5.19M |
| Net cash used for financing activities | -$-2.77M | -$-2.76M | -$-460K | -$-3.12M | -$-5.19M |
| Net change in cash | -$-620K | -$-6.37M | $7.41M | $300K | -$-60K |
| Cash at end of period | $1.25M | $1.88M | $8.24M | $830K | $530K |
| Operating cash flow | $1.97M | $3.47M | $3.14M | $2.53M | $5.31M |
| Capital expenditure | -$-60K | -$-430K | -$-170K | -$-80K | -$-120K |
| Free cash flow | $1.91M | $3.03M | $2.98M | $2.45M | $5.2M |
Line items
Line items
Line items
About United-Guardian, Inc.
United-Guardian, Inc., operating both domestically and globally, specializes in the development, production, and distribution of a diverse range of cosmetic raw materials, pharmaceutical solutions, medical-grade lubricants, and proprietary industrial chemicals. Its extensive cosmetic ingredients catalog includes the LUBRAJEL line of water-based moisturizing and lubricating gel formulations, featuring variants such as LUBRAJEL NATURAL (derived from natural sources), LUBRAJEL MARINE, and LUBRASIL II SB (a silicone-infused LUBRAJEL formulation). Other key offerings in this category are LUBRAJEL II XD; B-122, a powdered lubricant suitable for pressed powders, eyeliners, blushes, and industrial uses; KLENSOFT, a surfactant for shampoos, shower gels, and makeup removers; and ORCHID COMPLEX, an oil-soluble base for skin creams, lotions, and cleansers. For medical applications, United-Guardian provides lubricants like LUBRAJEL RR and RC, which are water-based gels specifically designed for urinary catheters. LUBRAJEL MG serves to lubricate urinary catheters, pre-lubricated enema tips, and other medical devices. The company also offers LUBRAJEL LC and LUBRAJEL FA, specialized LUBRAJEL formulations tailored for oral care, alongside LUBRAJEL FLUID for lubricating various water-soluble products. The pharmaceutical portfolio features RENACIDIN, a prescription medication for preventing and dissolving calcifications in urethral catheters and the urinary bladder. Also included is CLORPACTIN WCS-90, an antimicrobial agent effective against infections in the urinary bladder, localized peritoneal infections, and infections affecting the eyes, ears, nose, throat, and sinuses. Industrial products comprise DESELEX, a sequestering and chelating agent vital for detergent manufacturing, and THOROCLENS, a powerful chlorine-based industrial cleaning solution. The firm also dedicates resources to research and development, primarily focusing on advancing cosmetic ingredients. Products are brought to market through a robust network of marketing partners, distributors, and wholesalers. Established in 1942, United-Guardian maintains its headquarters in Hauppauge, New York.
- CEO
- Donna Vigilante
- Employees
- 25
- Beta
- 0.96
Explore
Frequently asked questions
What is the intrinsic value of United-Guardian, Inc. (UG)?
InvestorsCraft does not currently publish an intrinsic value for UG. How the IC value is calculated.
Is UG undervalued?
InvestorsCraft does not publish an undervaluation signal for UG at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.